Streetwise Reports Examines Biotech with Alzheimer's Therapy that Analyst Calls a 'High Risk, High Reward Opportunity'

SAN FRANCISCO, CA--(Marketwired - October 26, 2017) - Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease.

Included in this article is: ProMIS Neurosciences Inc. (TSX: PMN)

In an Oct. 17 research report, Mackie analyst Andre Uddin wrote that ProMIS Neurosciences Inc.'s lead Alzheimer's monoclonal antibody (mAb) therapeutic PMN310 showed a "high degree of selectivity to target amyloid beta oligomers when compared to other amyloid beta-directed mAbs in a preclinical study."

In the study, ProMIS "compared the binding profiles of PMN310, Eli Lilly's solanezumab (failed in a pivotal study), Johnson & Johnson/Pfizer's bapineuzumab (discontinued) and Biogen's aducanumab to amyloid beta monomers, oligomers and plaques," Uddin explained.

Uddin highlighted the results revealed that PMN310 bound only to select oligomers. In contrast, "solanezumab mainly bound to the monomers; bapineuzumab bound to all forms of amyloid beta (monomers, plaques, oligomers); [and] aducanumab bound to both plaques and oligomers."

The findings are significant for ProMIS, Uddin argued, because "increasing scientific evidence suggests that Alzheimer's is primarily caused by soluble toxic amyloid beta oligomers," and the company is developing PMN310 based on that theory.

Continue reading this article: Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'